GU Oncology Now Journal

Issue 10

Highlights from Issue 10

  1. Molecular Subtyping to Stratify Treatment of Muscle-Invasive Bladder Cancer: A Cost Effectiveness Analysis
  2. Use of CxBladder Monitor During the COVID-19 Pandemic Reduces Frequency of Surveillance Cystoscopy
  3. Differentiation of Benign from Malignant Solid Renal Masses with Multiparametric MRI using the De Silva St George classification scheme
  4. Transurethral Resection of Bladder Tumor with Blue-Light Cystoscopy More Cost Effective than White-Light Cystoscopy after Third Year
  5. Clinical and Genomic Predictors of Pathologic Upstaging in Newly Diagnosed High-grade T1 Non-Muscle Invasive Bladder Cancer

Read the Issue

Read the Issue

Read the Issue

Read the Issue

Read the Issue

Read the Issue

Read the Issue

Read the Issue

Read the Issue

GU Oncology Issue 1

Welcome to GU Oncology Now!

The theme of this inaugural issue is New Therapeutics in Advanced Prostate Cancer with information on new prostate cancer treatments, plus the clinical trials you will want to follow and the newest FDA-approved medications.

We are extremely pleased to offer interviews with two widely recognized experts in the field. Andrei Iagaru, MD, Professor of Radiology – Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford Health Care, discusses the latest updates in prostate cancer imaging using positron emission tomography (PET).

Scott T. Tagawa, MD, Professor of Medicine and Urology at Weill Cornell Medicine, and Attending Physician at New York-Presbyterian – Weill Cornell Medical Center, explains the benefits and roadblocks of prostate-specific membrane antigen (PSMA)-targeting in prostate cancer treatment, as well as upcoming therapies in the pipeline for prostate cancer treatment.

Read the Issue

Curated Journal reading List